⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 2, 2024Open Access

Figure S4 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Francesca Zammarchi Karin Havenith Nikoleta Sachini Narinder Janghra Simon Chivers Esohe Idusogie Eugenio Gaudio Chiara Tarantelli François Bertelli Kathleen Santos Peter Tyrer Simon Corbett Filippo Spriano Gaetanina Golino Luciano Cascione Francesco Bertoni John A. Hartley Patrick H. van Berkel

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Fig. S4. Time course of DNA ICL formation in KARPAS-299 cells following a 2-hour treatment with ADCT-602 or SG3199. Results are presented as a mean percentage decrease in OTM ± SD (n = 4). ICL interstrand crosslinking; OTM Olive tail moment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zammarchi et al. (2024) studied this question.

synapsesocial.com/papers/68e70c5ab6db643587686167 https://doi.org/10.1158/1535-7163.25523307.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
2Figure S2 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
3Figure S9 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
4Figure S5 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024
5Figure S3 from ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies2024